TLANDO

Asset

Oral testosterone undecanoate formulation providing testosterone replacement therapy.

Stage: Approved
Modality: Small molecule
Target: AR; 1
Indication: 0
Trials: 1
Developer

Indications

1

Hypogonadism
Approved, prnewswire.com, 7 Oct 2026

In the full profile

Targets and what it contains1
Owner and partners2
Evidence for its targets1
Competitors7
Signals1

Every asset’s record: target, stage, trials and the evidence behind it.

Updated 7 Oct 2026, 1 source